الفهرس 
Intrauterine Growth RestrictionOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Intrauterine growth restriction (IUGR) is associated with stillbirth, neonatal death, and perinatal morbidity as well as delayed effects including cerebral palsy (CP) and adult diseases. In most cases, IUGR is due to placental insufficiency but may also be due to a number of other conditions such as congenital anomalies, infections, or drug and substance misuse. Defective placentation leads to inability of the fetus to achieve its full growth potential. Many problems for the fetus and the neonate could occur such as intrauterine demise, neonatal death and severe short or long term morbidities. As previously established there is no method for precise identification of intrauterine growth restricted babies antenatally. The most critical decision is the timing of delivery of those restricted fetuses. Doppler ultrasonography has been shown to improve outcome in intrauterine growth restricted fetuses. There is no current treatment available for intrauterine growth restriction (IUGR); the only management option obstetricians can offer is early birth. Maternal dexamethasone administration to pregnant women at risk of preterm labor improves the blood flow of the maternal uterine artery, fetal middle cerebral artery (MCA) and umbilical artery (UA) 24 h after its administration. The beneficial effect of its administration is consistent regardless of the gestational age and fetal weight.